Aelis Farma study suggests AEF0217 improves daily functioning in people with Down syndrome

• Aelis Farma announced positive retrospective study results suggesting AEF0217 improved everyday functioning in people with Down syndrome.
• Caregivers reported improvements in independence, social interactions and communication compared with placebo.
• The analysis covered 22 caregivers from a previous randomized Phase 1/2 trial; it was not designed to independently establish efficacy.
• A multinational Phase 2b trial is underway, with results expected by the end of 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aelis Farma SA published the original content used to generate this news brief on November 06, 2026, and is solely responsible for the information contained therein.